• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Activation of RIG-I signaling to increase the pro-inflammatory phenotype of a tumor.激活RIG-I信号传导以增强肿瘤的促炎表型。
Oncotarget. 2019 Mar 22;10(24):2338-2339. doi: 10.18632/oncotarget.26729.
2
Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment.利用肿瘤微环境中的视黄酸诱导基因I（RIG-I）和固有免疫进行癌症治疗
Oncotarget. 2018 Jun 22;9(48):29007-29017. doi: 10.18632/oncotarget.25626.
3
Direct RIG-I activation in human NK cells induces TRAIL-dependent cytotoxicity toward autologous melanoma cells.直接激活人自然杀伤细胞中的 RIG-I 可诱导 TRAIL 依赖性细胞毒性作用杀伤自体黑素瘤细胞。
Int J Cancer. 2019 Apr 1;144(7):1645-1656. doi: 10.1002/ijc.31874. Epub 2019 Jan 9.
4
Host and Viral Modulation of RIG-I-Mediated Antiviral Immunity.宿主与病毒对RIG-I介导的抗病毒免疫的调节
Front Immunol. 2017 Jan 3;7:662. doi: 10.3389/fimmu.2016.00662. eCollection 2016.
5
Delivery of 5'-triphosphate RNA with endosomolytic nanoparticles potently activates RIG-I to improve cancer immunotherapy.内溶酶体纳米颗粒递送 5'-三磷酸 RNA 可有效激活 RIG-I 以改善癌症免疫治疗。
Biomater Sci. 2019 Jan 29;7(2):547-559. doi: 10.1039/c8bm01064a.
6
RIG-I activating immunostimulatory RNA boosts the efficacy of anticancer vaccines and synergizes with immune checkpoint blockade.RIG-I 激活的免疫刺激性 RNA 增强了抗癌疫苗的疗效，并与免疫检查点阻断协同作用。
EBioMedicine. 2019 Mar;41:146-155. doi: 10.1016/j.ebiom.2019.02.056. Epub 2019 Mar 6.
7
Ubiquitin-like modifier FAT10 attenuates RIG-I mediated antiviral signaling by segregating activated RIG-I from its signaling platform.类泛素修饰因子FAT10通过将激活的视黄酸诱导基因I（RIG-I）与其信号平台分离，减弱RIG-I介导的抗病毒信号传导。
Sci Rep. 2016 Mar 21;6:23377. doi: 10.1038/srep23377.
8
Nasopharyngeal carcinoma progression is mediated by EBER-triggered inflammation via the RIG-I pathway.鼻咽癌进展是由EBER通过RIG-I途径引发的炎症介导的。
Cancer Lett. 2015 May 28;361(1):67-74. doi: 10.1016/j.canlet.2015.02.037. Epub 2015 Feb 23.
9
Involvement of zebrafish RIG-I in NF-κB and IFN signaling pathways: insights into functional conservation of RIG-I in antiviral innate immunity.斑马鱼RIG-I在NF-κB和IFN信号通路中的作用：深入了解RIG-I在抗病毒天然免疫中的功能保守性
Dev Comp Immunol. 2015 Jan;48(1):95-101. doi: 10.1016/j.dci.2014.09.008. Epub 2014 Oct 5.
10
Multifunctional antitumor molecule 5'-triphosphate siRNA combining glutaminase silencing and RIG-I activation.多功能抗肿瘤分子 5'-三磷酸 siRNA 结合谷氨酰胺酶沉默和 RIG-I 激活。
Int J Cancer. 2014 Apr 15;134(8):1958-71. doi: 10.1002/ijc.28416. Epub 2013 Dec 2.

引用本文的文献

1
An insight into the role of innate immune cells in breast tumor microenvironment.深入了解天然免疫细胞在乳腺肿瘤微环境中的作用。
Breast Cancer. 2025 Jan;32(1):79-100. doi: 10.1007/s12282-024-01645-8. Epub 2024 Oct 26.
2
Exploiting RIG-I-like receptor pathway for cancer immunotherapy.利用 RIG-I 样受体通路进行癌症免疫治疗。
J Hematol Oncol. 2023 Feb 8;16(1):8. doi: 10.1186/s13045-023-01405-9.
3
Treatment with a retinoic acid-inducible gene I (RIG-I) agonist as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors: results from two phase 1 studies.在晚期实体瘤患者中单用和联合帕博利珠单抗使用视黄酸诱导基因 I（RIG-I）激动剂治疗的结果：两项 I 期研究的结果。
Cancer Immunol Immunother. 2022 Dec;71(12):2985-2998. doi: 10.1007/s00262-022-03191-8. Epub 2022 May 21.
4
Engaging Pattern Recognition Receptors in Solid Tumors to Generate Systemic Antitumor Immunity.激活实体瘤中的模式识别受体以产生全身性抗肿瘤免疫。
Cancer Treat Res. 2022;183:91-129. doi: 10.1007/978-3-030-96376-7_3.
5
Harnessing the Activation of RIG-I Like Receptors to Inhibit Glioblastoma Tumorigenesis.利用视黄酸诱导基因I样受体的激活来抑制胶质母细胞瘤的肿瘤发生。
Front Mol Neurosci. 2021 Jul 8;14:710171. doi: 10.3389/fnmol.2021.710171. eCollection 2021.
6
The Innate Immune Signalling Pathways: Turning RIG-I Sensor Activation Against Cancer.固有免疫信号通路：将RIG-I传感器激活用于对抗癌症
Cancers (Basel). 2020 Oct 27;12(11):3158. doi: 10.3390/cancers12113158.
7
Limited MOMP, ATM, and their roles in carcinogenesis and cancer treatment.有限的线粒体膜通透性转换孔（MOMP）、共济失调毛细血管扩张突变基因（ATM）及其在致癌作用和癌症治疗中的作用。
Cell Biosci. 2020 Jun 18;10:81. doi: 10.1186/s13578-020-00442-y. eCollection 2020.
8
Comparative Structure and Function Analysis of the RIG-I-Like Receptors: RIG-I and MDA5.RIG-I 样受体：RIG-I 和 MDA5 的比较结构与功能分析。
Front Immunol. 2019 Jul 17;10:1586. doi: 10.3389/fimmu.2019.01586. eCollection 2019.

本文引用的文献

1
Therapeutically Active RIG-I Agonist Induces Immunogenic Tumor Cell Killing in Breast Cancers.治疗性活性 RIG-I 激动剂诱导乳腺癌中免疫原性肿瘤细胞杀伤。
Cancer Res. 2018 Nov 1;78(21):6183-6195. doi: 10.1158/0008-5472.CAN-18-0730. Epub 2018 Sep 17.
2
Cytosolic DNA Sensing in Organismal Tumor Control.机体肿瘤控制中的细胞质 DNA 感应。
Cancer Cell. 2018 Sep 10;34(3):361-378. doi: 10.1016/j.ccell.2018.05.013. Epub 2018 Jun 28.
3
Checkpoint blockade in the treatment of breast cancer: current status and future directions.检查点阻断在乳腺癌治疗中的应用：现状与未来方向。
Br J Cancer. 2018 Jul;119(1):4-11. doi: 10.1038/s41416-018-0126-6. Epub 2018 May 29.
4
A minimal RNA ligand for potent RIG-I activation in living mice.一种用于在活体小鼠中有效激活 RIG-I 的最小 RNA 配体。
Sci Adv. 2018 Feb 21;4(2):e1701854. doi: 10.1126/sciadv.1701854. eCollection 2018 Feb.
5
Checkpoint inhibitors in breast cancer - Current status.乳腺癌的检查点抑制剂：现状。
Cancer Treat Rev. 2018 Feb;63:122-134. doi: 10.1016/j.ctrv.2017.12.008. Epub 2017 Dec 14.
6
The immune contexture in cancer prognosis and treatment.癌症预后和治疗中的免疫结构。
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734. doi: 10.1038/nrclinonc.2017.101. Epub 2017 Jul 25.
7
pH-Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides.pH 响应性纳米颗粒疫苗用于双重递呈抗原和免疫刺激性寡核苷酸。
ACS Nano. 2013 May 28;7(5):3912-25. doi: 10.1021/nn305466z. Epub 2013 Apr 30.

Activation of RIG-I signaling to increase the pro-inflammatory phenotype of a tumor.

作者信息

Elion David L, Cook Rebecca S

机构信息

Cancer Biology Graduate Program, Vanderbilt University School of Medicine, Nashville, TN, USA; Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN, USA; Department of Biomedical Engineering, Vanderbilt University School of Engineering, Nashville, TN, USA; Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.

出版信息

Oncotarget. 2019 Mar 22;10(24):2338-2339. doi: 10.18632/oncotarget.26729.

DOI:10.18632/oncotarget.26729
PMID:31040925
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6481327/
Abstract
摘要